Item 5.02. |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On October 28, 2024, the Compensation Committee of the Board of Directors (the “Board”) of Coya Therapeutics, Inc. (the “Company”) approved certain employment agreements with Dr. Howard Berman (the “Berman Employment Agreement”), the Company’s outgoing Chief Executive Officer, and Dr. Arun Swaminathan (the “Swaminathan Employment Agreement”), the Company’s incoming Chief Executive Officer and current Chief Business Officer.
As previously disclosed, effective October 31, 2024, Dr. Berman resigned as the Company’s Chief Executive Officer and Dr. Swaminathan was appointed as the Company’s Chief Executive Officer, effective November 1, 2024. After his resignation, Dr. Berman remains a member of the Board.
Certain biographical information about Dr. Swaminathan was previously disclosed in the Company’s current report on Form 8-K, filed with the Securities and Exchange Commission on August 19, 2024, and is incorporated by reference herein.
Swaminathan Employment Agreement
The Swaminathan Employment Agreement provides for Dr. Swaminathan to serve as Chief Executive Officer and provides for an annual base salary of $525,000, subject to periodic review and adjustment in the sole discretion of the Board. In addition, Dr. Swaminathan is eligible to receive an annual bonus, which is targeted at up to 50% of his base salary but which may be adjusted by the Board based on achievement of goals and objectives established by the Company. Pursuant to the terms of the Swaminathan Employment Agreement, Dr. Swaminathan is eligible to receive, from time to time, equity awards under our existing equity incentive plan, or any other equity incentive plan the Company may adopt in the future, and the terms and conditions of such awards, if any, will be determined by the Board in its discretion.
If Dr. Swaminathan is terminated for Cause (as defined in the Swaminathan Employment Agreement), all severance obligations under the Swaminathan Employment Agreement cease, except for payment of any Accrued Obligations (as defined in the Swaminathan Employment Agreement). If Dr. Swaminathan is terminated without Cause, he is due continued payment of his annual base salary for 12 months, and a pro rata portion of his annual bonus for the fiscal year in which the termination occurs, each contingent upon Dr. Swaminathan executing a severance and general release agreement.
The Company or Dr. Swaminathan may terminate employment with the Company at any time, without any advance notice, for any reason or no reason at all.
Berman Employment Agreement
The Berman Employment Agreement provides for Dr. Berman to serve as Executive Chairman and provides for an annual base salary of $420,000. In addition, Dr. Berman is eligible to receive an annual bonus, which is targeted at up to 50% of his base salary but which may be adjusted by the Board based on achievement of goals and objectives established by the Company. Pursuant to the terms of the Berman Employment Agreement, Dr. Berman is eligible to receive, from time to time, equity awards under our existing equity incentive plan, or any other equity incentive plan the Company may adopt in the future, and the terms and conditions of such awards, if any, will be determined by the Board in its discretion.
If Dr. Berman is terminated for Cause (as defined in the Berman Employment Agreement), the Company’s obligations under the agreement cease entirely, with the exception of any Accrued Obligations (as defined in the Berman Employment Agreement). If Dr. Berman is terminated without Cause, he is entitled to continued payment of his base salary for a period of 12 months, and a prorated annual bonus for the fiscal year in which termination occurs, each contingent upon Dr. Berman’s execution of a severance and general release agreement.
The Company or Dr. Berman may terminate employment with the Company at any time, without any advance notice, for any reason or no reason at all.